NEW YORK – The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical trials. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. TCT, which will be held October 23-26, 2023 in San Francisco, California at the Moscone Center, will be celebrating 35 years of leading the field.

For more than three decades, TCT has ignited innovation, education, and connection in interventional cardiology, with the purpose of improving the survival and quality of life of patients suffering from heart and vascular disease. Every year, TCT features cutting-edge research in interventional cardiovascular medicine that directly impacts patient care and how physicians treat heart disease.

In the fast-paced world of medical advancements, late-breaking trials are highly anticipated and offer clinicians the opportunity to learn about new interventions, drugs, techniques, or strategies that could potentially improve patient outcomes. The 12 studies selected for presentation at TCT examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that demonstrate potential to treat or prevent cardiovascular disease. Late-breaking trials will be presented during the main sessions and highlighted during press conferences scheduled for Tuesday, October 24, Wednesday, October 25, and Thursday, October 26.

Below are late-breaking clinical trials focusing on the topic of transcatheter aortic valve replacement (TAVR):

• PARTNER 3 Low-Risk

Five-Year Clinical and Echocardiographic Outcomes from The PARTNER 3 Low-Risk Randomized Trial

Martin B. Leon

• EVOLUT Low Risk

Four-Year Outcomes from the EVOLUT Low Risk Trial

Michael J. Reardon

• WATCH TAVR

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement — The WATCH TAVR Trial

Samir R. Kapadia

• ALIGN-AR

Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement System in High-Risk Patients with Symptomatic Severe Native Aortic Regurgitation

Vinod H. Thourani

• VIVA

Transcatheter versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annuli: A Randomized Clinical Trial (the VIVA Trial)

Josep Rodés-Cabau

The Program Guide can be found here: https://tct2023.crfconnect.com/program-guide.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 30 years, CRF has helped accelerate medical breakthroughs and educated doctors on the latest treatments for heart disease. CRF’s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Every year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

Keep reading about the latest in TAVR research:

TVT 2023: The Structural Heart Summit Newsroom

TCT 2023 Newsroom